Three evaluable patients were entered at each dose level. were dose dependent, with a mean terminal half-life (t1/2) of 26399?hours GNE-049 for the 720?mg dose. Clinical benefit in 15 out of 30 (50%) evaluable patients included one ongoing complete response, two partial remissions lasting 16 and 77 weeks and disease stabilisation (SD) in 12 patients […]